TL;DR
Findings support UAB as a multifunctional lipid-mimetic component and bioactive partner for DOX co-delivery and the greatest tumor suppression without overt short-term organ injury in hepatocellular carcinoma-bearing mice.
The potential of PEG-HA-EGCG micelles as a polysaccharide-based nanoplatform integrating high-capacity drug loading, tumor-responsive release, and targeted intracellular delivery for cancer therapy is demonstrated.
A glutathione-responsive nanocarrier system based on poly(lactic-co-glycolic acid) (PLGA) was designed, which introduced disulphide bonds that are stable in extracellular environments but cleaved in a reductive intracellular environment enriched with glutathione, demonstrating promising therapeutic efficacy.
Oral administration remains the most convenient and patient-preferred route for therapeutic drug delivery. However, the clinical translation of oral doxorubicin (DOX) is severely hampered by its low oral bioavailability, which remains a major challenge for oral chemotherapy. Herein, we report the development of taurine...
Niosomal delivery systems have emerged as promising nanocarriers for improving the delivery and therapeutic performance of anticancer agents. The chemotherapeutic agent docetaxel and the phytochemical lemongrass oil were separately encapsulated into niosomal formulations to evaluate whether niosomal delivery could enha...
In cytotoxicity assays, CA-Lipo-MIL demonstrated stronger antiproliferative activity than free cinnamaldehyde (CA-Bulk) against HT-29 and MDA-MB-231 cancer cells, showing enhanced apoptosis marker modulation versus free CA, enhancing anticancer efficacy and minimizing systemic toxicity.
Background: Triple-negative breast cancer (TNBC) is an aggressive malignancy associated with limited targeted therapeutic options, high relapse rates, and considerable toxicity from conventional chemotherapy. Doxorubicin (DOX) remains an important therapeutic agent, but its clinical utility is limited by systemic toxic...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
